Clinical Trials Logo

Myelofibrosis clinical trials

View clinical trials related to Myelofibrosis.

Filter by:

NCT ID: NCT00087672 Completed - Myelofibrosis Clinical Trials

A Phase II Study of CC-5013 in Myelofibrosis

Start date: July 2004
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.

NCT ID: NCT00081874 Completed - Leukemia Clinical Trials

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Start date: April 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis. Another goal is to learn how effective the dose that is found is as a treatment.

NCT ID: NCT00069680 Completed - Myelofibrosis Clinical Trials

Genetic Analysis of Gray Platelet Syndrome

Start date: September 29, 2003
Phase:
Study type: Observational

This study will identify and characterize the gene or genes responsible for Gray Platelet syndrome (GPS). Platelets are small blood cells that stick on injured blood vessels to form a plug and stop bleeding. When a blood vessel is injured (like a cut on a finger), platelets release the proteins stored in their sacs to help form a blood clot. Patients with GPS bleed longer than other people because their platelets lack some of these protein-carrying sacs. Platelets without sacs look pale gray under the microscope rather than pink, giving the syndrome its name. Except for rare patients with severe hemorrhage, the bleeding tendency in GPS is usually mild to moderate, with patients experiencing easy bruising, nosebleeds, and, in women, excessive menstrual bleeding. Patients with GPS and members of their family with GPS may be eligible for this study. Participants will provide a personal and family medical history and will have blood drawn. About 1 to 2 tablespoons of blood will be drawn in adults, and about 1 teaspoon in children. The blood will be analyzed for genes that cause GPS